Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07466927) titled 'Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases' on March 9.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Fudan University
Condition:
HER2-negative Breast Cancer
Intervention:
Drug: SHR-A1811
Drug: SKB264
Drug: Pembrolizumab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: March 15, 2026
Target Sample Size: 30
Countries of Recruitment:
China
To know mor...